BR112016010643A2 - peptídeo - Google Patents

peptídeo

Info

Publication number
BR112016010643A2
BR112016010643A2 BR112016010643A BR112016010643A BR112016010643A2 BR 112016010643 A2 BR112016010643 A2 BR 112016010643A2 BR 112016010643 A BR112016010643 A BR 112016010643A BR 112016010643 A BR112016010643 A BR 112016010643A BR 112016010643 A2 BR112016010643 A2 BR 112016010643A2
Authority
BR
Brazil
Prior art keywords
poorly regulated
sequence
terminus
amino acid
food intake
Prior art date
Application number
BR112016010643A
Other languages
English (en)
Inventor
Henriksen Kim
Vietz Andreassen Kim
Karsdal Morten
Original Assignee
Keybioscience Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201320112A external-priority patent/GB201320112D0/en
Priority claimed from GB201414706A external-priority patent/GB201414706D0/en
Application filed by Keybioscience Ag filed Critical Keybioscience Ag
Publication of BR112016010643A2 publication Critical patent/BR112016010643A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

peptídeos miméticos de calcitonina tendo uma sequência de aminoácidos de acordo com seq id no:8 ou seq id no:53, cada uma das quais pode ser carboxilada no seu n-terminal ou de outra forma modificada para reduzir a carga positiva do primeiro aminoácido e independentemente da que pode ser amidada no seu c-terminal e em cada uma das quais os resíduos de cisteína das posições 1 e 7 podem, juntos, ser substituídos por ácido a-aminosubérico (asu), que é usado como medicamento para tratar diabetes (tipo i e/ou tipo ii), excesso de peso corporal, consumo excessivo de alimento, síndrome metabólica, artrite reumatoide, doença hepática gordurosa não alcoólica, osteoporose ou osteoartrite, níveis de glicose sanguínea fracamente regulados, resposta fracamente regulada aos testes de tolerância à glicose ou ingestão de alimento fracamente regulada.
BR112016010643A 2013-11-14 2014-11-10 peptídeo BR112016010643A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201320112A GB201320112D0 (en) 2013-11-14 2013-11-14 Calcitonin Mimetics for treating diseases and disorders
GB201414706A GB201414706D0 (en) 2014-08-19 2014-08-19 Calcitonin mimetics for treating diseases and disorders
PCT/EP2014/074207 WO2015071229A1 (en) 2013-11-14 2014-11-10 Calcitonin mimetics for treating diseases and disorders

Publications (1)

Publication Number Publication Date
BR112016010643A2 true BR112016010643A2 (pt) 2017-12-05

Family

ID=51947308

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016010643A BR112016010643A2 (pt) 2013-11-14 2014-11-10 peptídeo

Country Status (24)

Country Link
US (2) US10232021B2 (pt)
EP (3) EP3321278B1 (pt)
JP (1) JP6639389B2 (pt)
KR (1) KR20160075794A (pt)
CN (1) CN105722854B (pt)
AU (2) AU2014350328B2 (pt)
BR (1) BR112016010643A2 (pt)
CA (1) CA2928654A1 (pt)
CY (2) CY1119976T1 (pt)
DK (2) DK3068796T3 (pt)
ES (2) ES2713851T3 (pt)
HR (2) HRP20180337T1 (pt)
HU (2) HUE044465T2 (pt)
LT (2) LT3321278T (pt)
MX (1) MX2016006049A (pt)
NO (1) NO3068796T3 (pt)
PH (1) PH12016500705B1 (pt)
PL (2) PL3068796T3 (pt)
PT (2) PT3321278T (pt)
RS (2) RS57152B1 (pt)
RU (1) RU2689551C1 (pt)
SI (2) SI3068796T1 (pt)
TR (1) TR201802765T4 (pt)
WO (1) WO2015071229A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201500263D0 (en) * 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
KR101869595B1 (ko) 2016-06-08 2018-06-21 부경대학교 산학협력단 성게 유래 칼시토닌 유사 펩타이드를 유효성분으로 포함하는 골 질환 예방 또는 치료용 조성물
CN108424460A (zh) * 2017-02-13 2018-08-21 成都贝爱特生物科技有限公司 GLP-1类似物和davalintide类似物的融合蛋白制备及其用途
CN106880835A (zh) * 2017-02-17 2017-06-23 云南同方科技有限公司 用于缓解高血压症状的植物精油复合物制备及应用
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
CA3156452A1 (en) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh NPY2 RECEPTOR AGONISTS
KR20230045088A (ko) 2020-08-07 2023-04-04 베링거 인겔하임 인터내셔날 게엠베하 가용성 npy2 수용체 작용제
AR124295A1 (es) 2020-12-18 2023-03-15 Lilly Co Eli Agonistas duales del receptor de amilina y calcitonina y usos de los mismos
WO2024050289A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
JPH03240797A (ja) * 1990-02-15 1991-10-28 Sagami Chem Res Center 新規カルシトニン誘導体
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
JPH04149198A (ja) * 1990-10-12 1992-05-22 Sagami Chem Res Center カルシトニン誘導体
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2285658C (en) 1997-04-16 2011-10-04 Nozar M. Mehta Direct expression of peptides into culture media
DE19736457C2 (de) * 1997-08-21 2001-08-23 Fraunhofer Ges Forschung Calcitonin-Derivate mit einer Verbrückung zwischen den Aminosäuren an den Positionen 17 und 21
EP1137431A1 (en) 1998-12-04 2001-10-04 Provalis UK Limited Pharmaceutical compositions containing insulin
CA2369591C (en) 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
JP2006521366A (ja) 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
CA2532565C (en) 2003-07-23 2012-05-08 Novartis Ag Use of calcitonin in osteoarthritis
EP1670500A2 (en) 2003-09-17 2006-06-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
EP1768676A1 (de) 2004-07-22 2007-04-04 ThioMatrix Forschungs- und Beratungs GmbH Verwendung von thiolgruppen-haltigen verbindungen als efflux-pumpen-hemmer
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
EP1907561B1 (en) 2005-06-24 2013-08-28 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
ATE515260T1 (de) 2006-03-13 2011-07-15 Advanced In Vitro Cell Technologies S L Stabile nanokapselsysteme für die verabreichung von wirkstoffen
MX2008012678A (es) 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
CN106971232B (zh) * 2011-10-25 2021-01-26 Nicira股份有限公司 网络控制系统中的控制器
CA2854175A1 (en) 2011-11-02 2013-05-10 Keybioscience Ag Peptide analogs for treating diseases and disorders

Also Published As

Publication number Publication date
NO3068796T3 (pt) 2018-06-30
US10232021B2 (en) 2019-03-19
JP2016538282A (ja) 2016-12-08
RS57152B1 (sr) 2018-07-31
TR201802765T4 (tr) 2018-03-21
LT3068796T (lt) 2018-05-10
CN105722854B (zh) 2020-08-04
PT3321278T (pt) 2019-03-19
EP3068796A1 (en) 2016-09-21
SI3068796T1 (en) 2018-05-31
EP3068796B1 (en) 2018-01-31
CA2928654A1 (en) 2015-05-21
MX2016006049A (es) 2016-08-12
PT3068796T (pt) 2018-03-02
US20170143800A1 (en) 2017-05-25
CY1121332T1 (el) 2020-05-29
PH12016500705A1 (en) 2016-05-30
LT3321278T (lt) 2019-03-12
RU2689551C1 (ru) 2019-05-28
ES2660788T3 (es) 2018-03-26
SI3321278T1 (sl) 2019-04-30
CN105722854A (zh) 2016-06-29
US20190142903A1 (en) 2019-05-16
HRP20180337T1 (hr) 2018-05-18
HUE037663T2 (hu) 2018-09-28
PL3068796T3 (pl) 2018-07-31
AU2018202480A1 (en) 2018-04-26
EP3470422A1 (en) 2019-04-17
CY1119976T1 (el) 2018-12-12
EP3321278B1 (en) 2019-01-09
KR20160075794A (ko) 2016-06-29
HRP20190356T1 (hr) 2019-04-19
PL3321278T3 (pl) 2019-06-28
JP6639389B2 (ja) 2020-02-05
RU2016123180A (ru) 2017-12-19
EP3321278A1 (en) 2018-05-16
AU2014350328A1 (en) 2016-05-19
RS58530B1 (sr) 2019-04-30
ES2713851T3 (es) 2019-05-24
DK3321278T3 (en) 2019-03-25
WO2015071229A1 (en) 2015-05-21
DK3068796T3 (en) 2018-03-05
PH12016500705B1 (en) 2016-05-30
AU2014350328B2 (en) 2018-04-05
HUE044465T2 (hu) 2019-10-28

Similar Documents

Publication Publication Date Title
BR112016010643A2 (pt) peptídeo
Harnedy et al. Blue whiting (Micromesistius poutassou) muscle protein hydrolysate with in vitro and in vivo antidiabetic properties
BR112018073511A2 (pt) polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
BR112012032708A2 (pt) proteína de fusão anticâncer.
BR112013032630A2 (pt) polipeptídeo heterodimerizado
PL397167A1 (pl) Przeciwnowotworowe bialko fuzyjne
BR112018075396A2 (pt) anticorpo neutralizante contra dengue para uso em um método de prevenção e/ou tratamento de infecção por zika
BR112016016411A2 (pt) VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
NZ754961A (en) Growth differentiation factor 15 (gdf-15) constructs
AR080229A1 (es) Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23)
BR112013008407A2 (pt) antígenos de clostridium difficile
BR112017001340A2 (pt) vacinas antidengue e anticorpos
BR112015032875A2 (pt) derivados de peptídeos do tipo glp-1, e usos dos mesmos
AR096162A1 (es) Péptidos terapéuticos
CR20180378A (es) Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
Tripathi et al. Identifying the critical domain of LL-37 involved in mediating neutrophil activation in the presence of influenza virus: Functional and structural analysis
BR112013025975A2 (pt) proteína de fusão anticancerígena
BR112019000098A2 (pt) proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio
BR112015018265A2 (pt) Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas
Tota et al. New biological aspects of chromogranin A-derived peptides: focus on vasostatins
BR112016002572A2 (pt) peptídeos
D'Amour et al. Carboxyl-terminal parathyroid hormone fragments: role in parathyroid hormone physiopathology
BR112018012055A2 (pt) substrato de transglutaminase (tg) recombinante, método in vitro para marcar uma proteína de interesse, composição farmacêutica ou de diagnóstico e kit de diagnóstico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time